Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Besides Keytruda, there are only 2 other approved oncology drugs in Merck's portfolio.
Merck's recent $10.8B acquisition of Prometheus Biosciences is expected to negatively impact earnings per share by approximately $0.25 in the first 12 months.